US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

8.65

-2.4500-22.07%

Post-market: 8.16-0.4900-5.66%19:30 EDT

Volume:639.38K

Turnover:6.10M

Market Cap:426.00M

PE:-1.92

High:11.32

Open:11.21

Low:8.56

Close:11.10

52wk High:17.82

52wk Low:8.56

Shares:49.25M

Float Shares:13.84M

Volume Ratio:5.14

T/O Rate:4.62%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:4.10

PE(LYR):-0.05

Loading ...

Overview Company News Filings

AgomAb Therapeutics Initiated at Overweight by Cantor Fitzgerald

Agomab initiated with an Overweight at Cantor Fitzgerald

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)

Agomab Therapeutics Shareholders Vote on Director Nominees Marino Garcia, Naimish Patel at Sept. 11 Meeting

Agomab Therapeutics Announces Shareholder Meetings

Agomab Announces Proposed Appointments of Marino Garcia and DR. Naimish Patel to Board of Directors

THOMSON REUTERS

Press Release: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

AgomAb Therapeutics H1 EPS $(0.93)

Benzinga Earnings

Agomab FY26 H1 Net Loss Widens to €30.97 Million

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

THOMSON REUTERS

Agomab Therapeutics Initiated at Buy by B. Riley Securities

B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target

MT Newswires Live

Analysts’ Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)

Agomab Therapeutics Nv : B. Riley Initiates Coverage with Buy Rating; Target Price $34

THOMSON REUTERS

Agomab Therapeutics NV trading halted, volatility trading pause

NASDAQ Trade Halt Volatility Trading Pause at 03:51 Pm

European Equities Traded in the US as American Depositary Receipts Decline Friday

MT Newswires Live

Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment

Agomab announces NOV-ERA study design

Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/AGMB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":8.65,"timestamp":1790884800000,"preClose":11.1,"halted":0,"volume":639376,"hourTrading":{"tag":"盘后","latestPrice":8.16,"preClose":8.65,"latestTime":"19:30 EDT","volume":111429,"amount":961636.4525,"timestamp":1790897404514,"change":-0.49,"changeRate":-0.056647,"amplitude":0.056647},"delay":0,"changeRate":-0.22072072072072066,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Closed","change":-2.45,"latestTime":"10-01 16:00:00 EDT","open":11.21,"high":11.3224,"low":8.56,"amount":6095905.411648,"amplitude":0.248865,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.51426,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.1,"preHourTrading":{"tag":"盘前","latestPrice":11.5,"preClose":11.1,"latestTime":"09:06 EDT","volume":2185,"amount":25474.047554999997,"timestamp":1790860001633,"change":0.4,"changeRate":0.036036,"amplitude":0.087387},"postHourTrading":{"tag":"盘后","latestPrice":8.16,"preClose":8.65,"latestTime":"19:30 EDT","volume":111429,"amount":961636.4525,"timestamp":1790897404514,"change":-0.49,"changeRate":-0.056647,"amplitude":0.056647},"volumeRatio":5.135121},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":5.135121,"shares":49248000,"dividePrice":0,"high":11.3224,"amplitude":0.248865,"preClose":11.1,"low":8.56,"week52Low":8.56,"pbRate":"4.10","week52High":17.82,"institutionHeld":0,"latestPrice":8.65,"eps":-4.51426,"divideRate":0,"volume":639376,"delay":0,"ttmEps":-4.51426,"open":11.21,"prevYearClose":16,"prevWeekClose":10.51,"prevMonthClose":11.1,"prevQuarterClose":11.1,"fiveDayClose":10.58,"twentyDayClose":13.66,"sixtyDayClose":12.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-30","current":-1.91615,"percent":0.950311,"low":-14.725744,"twenty":-11.126198,"median":-8.776817,"eighty":-7.627138,"high":-6.52172,"avg":-9.433798,"sd":2.193394,"marketCap":518581176},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-18","current":-7.774516,"twenty":-11.657926,"median":-8.880371,"eighty":-7.795572,"marketCap":594915538},{"date":"2026-09-25","current":-6.876368,"twenty":-11.321652,"median":-8.807045,"eighty":-7.758992,"marketCap":521043575},{"date":"2026-09-30","current":-6.851652,"twenty":-11.126198,"median":-8.776817,"eighty":-7.627138,"marketCap":518581176}],"updateTime":1790902038191},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660244248","title":"AgomAb Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2660244248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660244248?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:45","pubTimestamp":1787136300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444293","title":"Agomab initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444293","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660444293?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:15","pubTimestamp":1787134507,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Agomab (AGMB) with an Overweight rating. Published first on TheFly – the ultimat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480044","title":"Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480044","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480044?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:01","pubTimestamp":1786971667,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fortrea-holdings-inc-ftre-agomab-therapeutics-nv-adr-agmb-and-sana-biotechnology-sana-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fortrea-holdings-inc-ftre-agomab-therapeutics-nv-adr-agmb-and-sana-biotechnology-sana-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4121","BK4588","LABU","AADR","CVY","LU0128526141.USD","SAPH","DIVL","FTRE","APIE","XBI","BK4585","BK4137","LU0029874061.USD","AGMB","ARMH","DINT","HCSG","BK4007","SANA","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658883954","title":"Agomab Therapeutics Shareholders Vote on Director Nominees Marino Garcia, Naimish Patel at Sept. 11 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2658883954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658883954?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:46","pubTimestamp":1786394787,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics shareholders vote on director nominees Marino Garcia, Naimish Patel at Sept. 11 meetingAgomab Therapeutics shareholders will vote Sept. 11, 2026 on adding two non-executive directo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLPMSvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658595978","title":"Agomab Therapeutics Announces Shareholder Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2658595978","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658595978?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:19","pubTimestamp":1786393162,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics announces shareholder meetingsAgomab will hold a Special General Meeting in Antwerp, Belgium on Sept. 11, 2026.Shareholders will vote on proposed appointments of Marino Garcia and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLbNgrln:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4007","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","BCDF","IE00BKPKM429.USD","AGMB","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658846959","title":"Agomab Announces Proposed Appointments of Marino Garcia and DR. Naimish Patel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658846959","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658846959?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:07","pubTimestamp":1786392435,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUABJ4SDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658596039","title":"Press Release: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658596039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658596039?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:07","pubTimestamp":1786392420,"startTime":"0","endTime":"0","summary":"approval at the Company's Special General Meeting to be held on September. -- The Company also announced that it will hold an Extraordinary General. Shareholders' Meeting to obtain shareholder approval for the proposed","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007","IPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666647","title":"AgomAb Therapeutics H1 EPS $(0.93)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666647","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666647?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:52","pubTimestamp":1786053125,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics (NASDAQ:AGMB) reported quarterly losses of $(0.93) per share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61026366/agomab-therapeutics-h1-eps-0-93","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AgomAb Therapeutics H1 EPS $(0.93)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756652","title":"Agomab FY26 H1 Net Loss Widens to €30.97 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756652","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756652?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046565,"startTime":"0","endTime":"0","summary":"Agomab FY26 H1 net loss widens to 30.97 millionAgomab posted a net loss of EUR 31 million for the six months ended June 30, 2026, widening from EUR 26.9 million a year earlier.R&D expense edged up to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL92jydC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","BK4007","BK4112","BCDF","IE00B3QW5Z07.USD","AGMB","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652239","title":"Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652239?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA12YZKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726762","title":"Agomab Therapeutics Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653726762?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:24","pubTimestamp":1784816640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings(END) Dow Jones NewswiresJuly 23, 2026 10:24 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","AGMB","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653975740","title":"B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2653975740","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653975740?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:22","pubTimestamp":1784809320,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics NV ADR (AGMB) has an average rating of buy and mean price target of $32.53, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653771773","title":"Analysts’ Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653771773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653771773?lang=en_us&edition=fundamental","pubTime":"2026-07-23 16:00","pubTimestamp":1784793639,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmac...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-agomab-therapeutics-nv-adr-agmb-milestone-pharmaceuticals-mist-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-agomab-therapeutics-nv-adr-agmb-milestone-pharmaceuticals-mist-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAPH","LU0128526141.USD","AADR","LABU","HCSG","BK4585","MIST","APIE","DINT","ARMH","BK4007","AGMB","CVY","BK4137","BK4581","XBI","BK4588","DIVL","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653185787","title":"Agomab Therapeutics Nv : B. Riley Initiates Coverage with Buy Rating; Target Price $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2653185787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653185787?lang=en_us&edition=fundamental","pubTime":"2026-07-23 10:46","pubTimestamp":1784774771,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43O16S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647047703","title":"Agomab Therapeutics NV trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2647047703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647047703?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:56","pubTimestamp":1782762961,"startTime":"0","endTime":"0","summary":"15:51 EDT Agomab (AGMB) Therapeutics NV trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-therapeutics-nv-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-therapeutics-nv-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647304500","title":"NASDAQ Trade Halt Volatility Trading Pause at 03:51 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2647304500","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647304500?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:51","pubTimestamp":1782762704,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 03:51 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nAQN2M63L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646366992","title":"European Equities Traded in the US as American Depositary Receipts Decline Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366992","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646366992?lang=en_us&edition=fundamental","pubTime":"2026-06-26 23:06","pubTimestamp":1782486382,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower Friday morning, decreasing 0.4% to 1,883.22 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech companies Evaxion  and Abivax , which gained 5.4% and 4.5% respectively. They were followed by healthcare firm Grifols  and drink and brewing giant Anheuser-Busch Inbev , which added 1.4% and 1.1%, respectively.The decliners from continental Europe were led by Agomab Therapeutics  and steel producer ArcelorMittal , which fell 3.9% and 3.5% respectively. They were followed by energy company Equinor , which was down 1.3%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways  and Autolus Therapeutics , which rose 5.6% and 2.8% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm  and Barclays , which shed 4% and 1.3% respectively.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4006","EVAX","BK4521","ADRU","EQNR","BK4141","BK4007","LU1232071149.USD","IE00BMPRXN33.USD","BK4158","ARMU","AGMB","BK4139","BK4588","LU0348723411.USD","GRFS","LU2543165471.USD","BK4561","BK4201","ARMW","BK4207","BK4609","ARM","CMPS","ARMG","BUD","MT","ABVX","IE00BMPRXQ63.HKD","AUTL","BK4585","LU0081259029.USD","BCS","BK4543","IE00BMPRXR70.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645915854","title":"Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645915854","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645915854?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:14","pubTimestamp":1782249240,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reached alignment with the Food and Drug Administration on the design of a Phase 2b study for patients with Crohn's disease who develop intestinal narrowings that can block food and often lead to surgery.The study will test Agomab's experimental pill, ontunisertib, against placebo in up to 320 adults, the Belgium-based company said Tuesday. Doctors will check at 24 weeks whether a scope can pass through the narrowed section of the intestine, which is a practical way to see if the blockage is easing. The trial will also follow patients to 52 weeks to track longer-term outcomes.Agomab said the protocol has been filed with the FDA and cleared a central ethics review in the U.S., and the study has Health Canada approval. The company has also submitted clinical trial applications in Europe and parts of Asia. The first patient is expected to be dosed in the second half of this year.Crohn's is a chronic progressive disease of the gastrointestinal tract. About 46% of all pa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AGMB","LABU","BK4080","ADC","BK4231","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645485922","title":"Agomab announces NOV-ERA study design","url":"https://stock-news.laohu8.com/highlight/detail?id=2645485922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645485922?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:18","pubTimestamp":1782245926,"startTime":"0","endTime":"0","summary":"Agomab (AGMB) announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0061475181.USD","BK4179","NOV","BK4007","AGMB","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859954","title":"Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859954","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859954?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:06","pubTimestamp":1782245172,"startTime":"0","endTime":"0","summary":"Agomab secured FDA alignment on the Phase 2b NOV-ERA study design for ontunisertib in fibrostenosing Crohn’s disease.The protocol cleared central IRB review in the U.S. and received Health Canada authorization.First patient dosing is targeted for the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL3YCkJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD","AGMB","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","SG9999014039.USD","BK4588","SG9999014005.SGD","BK4112","BK4007","NDAQ","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}]}}